T
Tom Ehlen
Researcher at University of British Columbia
Publications - 24
Citations - 3175
Tom Ehlen is an academic researcher from University of British Columbia. The author has contributed to research in topics: Debulking & Cancer. The author has an hindex of 16, co-authored 24 publications receiving 2724 citations. Previous affiliations of Tom Ehlen include BC Cancer Agency.
Papers
More filters
Journal ArticleDOI
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Ignace Vergote,Claes G. Tropé,Frédéric Amant,G.B. Kristensen,Tom Ehlen,N Johnson,René H.M. Verheijen,Maria E. L. van der Burg,A. J. Lacave,Pierluigi Benedetti Panici,Gemma G. Kenter,Antonio Casado,Cesar Mendiola,Corneel Coens,Leen Verleye,Gavin Stuart,Sergio Pecorelli,Nicholas Reed +17 more
TL;DR: Neoadjuvant chemotherapy followed by interval debulking surgery was not inferior to primary debulked surgery followed by chemotherapy as a treatment option for patients with bulky stage IIIC or IV ovarian carcinoma in this study.
Journal ArticleDOI
A brief mindfulness-based cognitive behavioral intervention improves sexual functioning versus wait-list control in women treated for gynecologic cancer
Lori A. Brotto,Yvonne Erskine,Mark S. Carey,Tom Ehlen,Sarah J. Finlayson,Mark Heywood,Janice S. Kwon,Jessica N. McAlpine,Gavin Stuart,Sydney Thomson,Dianne Miller +10 more
TL;DR: A brief mindfulness-based intervention for sexual dysfunction in gynecologic cancer survivors compared to a wait-list control group was effective for improving sexual functioning.
Journal ArticleDOI
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
Ignace Vergote,Corneel Coens,Matthew Nankivell,Gunnar B. Kristensen,Parmar Mkb.,Tom Ehlen,Gordon C Jayson,N Johnson,Ann Marie Swart,René H.M. Verheijen,W G McCluggage,Timothy J. Perren,Pierluigi Benedetti Panici,Gemma G. Kenter,Antonio Casado,Cesar Mendiola,Gavin Stuart,Nicholas S. Reed,Sean Kehoe +18 more
TL;DR: Long-term follow-up data substantiate previous results showing that neoadjuvant chemotherapy and upfront debulking surgery result in similar overall survival in advanced tubo-ovarian cancer, with better survival in women with stage IV disease.
Journal ArticleDOI
Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer
Ignace Vergote,Frédéric Amant,Gunnar B. Kristensen,Tom Ehlen,Nicholas S. Reed,Antonio Casado +5 more
TL;DR: In this article, a new strategy with neoadjuvant chemotherapy followed by interval debulking surgery has been developed for advanced ovarian cancer and the post-operative complications and mortality rates were lower after interval debulekting than after primary debulkting surgery.
Journal Article
The role of the fallopian tube in ovarian cancer.
Alicia A. Tone,Shannon Salvador,Sarah J. Finlayson,Anna V. Tinker,Janice S. Kwon,Lee Ch,Cohen T,Tom Ehlen,Marette Lee,Mark S. Carey,Mark Heywood,J. Pike,Paul Hoskins,Gavin Stuart,Kenneth D. Swenerton,David G. Huntsman,C. B. Gilks,Dianne Miller,Jessica N. McAlpine +18 more
TL;DR: Salpingectomy has been used to prevent high grade serous carcinoma (HGSC) in women with BRCA1/2 mutation and up to 60% of unselected women with pelvic HGSC as discussed by the authors.